Medtronic Bravo
This article was originally published in The Gray Sheet
Executive Summary
U.S. launch of catheter-free esophageal pH monitoring system as a diagnostic for gastroesophageal reflux disease (GERD) is announced May 21. The capsule-sized radiotelemetry device was acquired along with Endonetics in December 2001 (1"The Gray Sheet" Dec. 24, 2001, In Brief). Other Medtronic gastroenterology devices under development include the Gatekeeper GERD repair system, Enterra therapy for gastroparesis and InterStim therapy for bowel control...
You may also be interested in...
Medtronic/Endonetics
Gastroesophageal reflux disease (GERD) technology developer Endonetics, acquired Dec. 19, is conducting U.S. trials of the Gatekeeper reflux repair system. The device non-invasively places a biomaterial to augment the lower esophageal sphincter. The privately held, San Diego firm's Bravo esophageal pH monitoring system is a catheter-free diagnostic for the condition. The two products will complement Medtronic's existing gastroenterology offerings, including the Enterra therapy for gastroparesis and other gastroenterology diagnostics...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.